Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease

Bronchodilators provide the mainstay of pharmacologic therapy for chronic obstructive pulmonary disease (COPD), and anticholinergic bronchodilators, in particular, appear to be the most effective. There are currently two anticholinergic agents available in the US for the treatment of COPD (ipratropi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of chronic obstructive pulmonary disease 2011-01, Vol.6 (default), p.457-466
Main Authors: Sims, Michael W, Panettieri, Jr, Reynold A
Format: Article
Language:English
Subjects:
Animals
Bronchodilator Agents - adverse effects
Bronchodilator Agents - pharmacokinetics
Bronchodilator Agents - therapeutic use
Evidence-Based Medicine
Humans
Lung - drug effects
Lung - physiopathology
Muscarinic Antagonists - adverse effects
Muscarinic Antagonists - pharmacokinetics
Muscarinic Antagonists - therapeutic use
Pulmonary Disease, Chronic Obstructive - diagnosis
Pulmonary Disease, Chronic Obstructive - drug therapy
Pulmonary Disease, Chronic Obstructive - physiopathology
Review
Time Factors
Treatment Outcome
Tropanes - adverse effects
Tropanes - pharmacokinetics
Tropanes - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bronchodilators provide the mainstay of pharmacologic therapy for chronic obstructive pulmonary disease (COPD), and anticholinergic bronchodilators, in particular, appear to be the most effective. There are currently two anticholinergic agents available in the US for the treatment of COPD (ipratropium bromide and tiotropium bromide), but several others are in various stages of development. Aclidinium bromide, a novel, long-acting, anticholinergic bronchodilator, is currently in Phase III trials for the management of COPD. Available evidence suggests that aclidinium is a safe and well tolerated drug with a relatively rapid onset and a sufficient duration of action to provide once-daily dosing. This article will provide a pharmacologic profile of aclidinium bromide and review the preclinical and clinical studies evaluating its safety and efficacy in the treatment of COPD.
ISSN:1178-2005
1176-9106
1178-2005
DOI:10.2147/COPD.S15524